series-b
Stage
3
Investors
About
Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat retinal eye diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company is advancing OPT-302, a VEGF-C/D 'trap' designed to improve visual outcomes when combined with existing treatments.
Explore Opthea's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.